Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Roche drops lupus TCE, retains autoimmune cell therapy interest
The company’s head of pharma told Fierce that Roche still has a strategy for developing cell therapies for autoimmune diseases.
James Waldron
Jul 23, 2026 4:51am
Lupin seeds US spinout with cash, clinical-stage cancer assets
Jul 21, 2026 8:20am
China approved the first solid tumor CAR-T. Will the US follow?
Jun 30, 2026 10:00am
Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped
May 5, 2026 9:15am
Janux axes solid tumor T-cell engager after poor ph. 1 showing
Apr 28, 2026 4:15am
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Apr 15, 2026 7:43am
